Artisan Partners, an investment management company, released its “Artisan Global Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, ...
Dr. Inderbir Gill - Founding Executive Director for USC Urology, Chairman of Urological Cancer Surgery at Keck School of Medicine of USC Dr. Brian Helfand - Division Chief of Urology, Endeavor Health, ...
PROCEPT BioRobotics trades at 2.9x forward EV/2026E revenue, a deep discount to peers, despite 27-33% guided revenue growth. Learn why PRCT stock is a buy.
Analysts' ratings for PROCEPT BioRobotics (NASDAQ:PRCT) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a concise overview of recent ratings by ...
SAN JOSE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative ...
The demand for robotics and automation continues to grow, particularly following the pandemic. As labor costs have escalated, companies have invested in labor-saving measures. Market forecasts project ...
PROCEPT BioRobotics (NASDAQ:PRCT) stock is trading on Monday after the company released better-than-expected third-quarter earnings. The company reported EPS loss of $(0.40), down from $(0.51) a year ...
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ranks among the top robotics to buy according to analysts. On August 7, Wells Fargo maintained its Overweight rating on PROCEPT BioRobotics Corporation ...
PROCEPT BioRobotics Corp. (NASDAQ:PRCT) is one of the best pure-play robotics stocks to buy now. PROCEPT BioRobotics Corp. (NASDAQ:PRCT) is among the best pure-play robotics stocks to buy now. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results